Astellas Pharma Inc. and Pfizer Inc. have amended the protocol for the registrational PROSPER trial of Xtandi (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The companies now anticipate PROSPER's top-line results will be available later this year. Previously the expected primary completion date for PROSPER was June 2019.
If the data readout from the PROSPER trial does eventually lead to approval, this would be significant for androgen receptor...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)